Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin

Chemotherapy

Volumn 55, Issue 1, 2008, Pages 28-35

  Ma, Meng ^a   Qu, Xian Jun ^a   Mu, Guo Ying ^b   Chen, Ming Hui ^a   Cheng, Yan Na ^a   Kokudo, Norihiro ^d   Tang, Wei ^d   Cui, Shu Xiang ^c  

^a SHANDONG UNIVERSITY   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cell growth inhibition; Des carboxy prothrombin; Human hepatocellular carcinoma cells; Vitamin K2

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DECARBOXYPROTHROMBIN; FARNOQUINONE; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL MIGRATION; CELL MOTILITY; CELL STRAIN HEPG2; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ELECTROIMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SUPERNATANT; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL DIVISION; DRUG EFFECT; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; CHEMILUMINESCENT MEASUREMENTS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PROTEIN PRECURSORS; PROTHROMBIN; VITAMIN K 2;

EID: 54949111321     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167022     Document Type: Article

References (26)

1. Santamaria E, Munoz J, Fernandez-Irigoven J, Prieto J, Corrales FJ: Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int 2007;27:163-173.
2. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH: PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72(suppl 1):52-57.
3. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M, Nakatani T: Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006;41:1214-1219.
4. Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, Oka H, Yamazaki O, Manabe T, Urano F, Chung H, Kudo M, Matsunaga T: Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008;49:223-232.
5. Naraki T, Kohno N, Saito H, Fujimoto Y, Ohhira M, Morita T, Kohgo Y: Gamma-carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochim Biophys Acta 2002;1586:287-298.
6. Tamano M, Sugaya H, Oguma M, Lijima M, Yoneda M, Murohisa T, Kojima K, Kuniyoshi T, Majima Y, Hashimoto T, Terano A: Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma. Hepatol Res 2002;22:261-269.
7. Fujikawa T, Shiraha H, Ueda N, Takaoka N, Kakanishi Y, Matsuo N, Tanaka S, Nishina S, Suzuki M, Takaki A, Sakaguchi K, Shiratori Y: Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem 2007;282:8741-8748.
8. Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y, Koike K, Takaki A, Shiratori Y: Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005;280:6409-6415.
9. Lawley WJ, Charlton AJ, Hughson AJ, Grundy HH, Brown PM, Jones A: Development of a cell culture/ELISA assay to detect anticoagulant rodenticides and its application to analysis of rodenticide treated grain. J Agric Food Chem 2006;54:1588-1593.
10. Kuwahara N, Higashi T, Nouso K, Ito T, Tsuji T: Immunohistochemical studies of PIVKA-II in hepatocellular carcinoma by indirect immunofluorescence. Acta Med Okayama 1995;49:19-24.
11. Hazra B, Das Sarma M, Kumar B, Basu S, Das K, Pandey BN, Mishra KP: Cytotoxicity of diospyrin and its derivatives in relation to the generation of reactive oxygen species in tumour cells in vitroandin vivo. Chemotherapy 2007;53:173-176.
12. Qu XJ, Yang JL, Russell PJ, Goldstein D: Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 2004;172:733-738.
13. Franken NA, Rodermond HM, Stap J, Haverman J, van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-2319.
14. Wada T, Sata M, Sato J, Tokairin Y, Machiya J, Hirama N, Arao T, Inoue S, Takabatake K, Shibata Y, Kubota I: Clarithromycin suppresses invasiveness of human lung adenocarcinoma cells. Chemotherapy 2007;53:77-84.
15. Okutucu B, Dincer A, Habib O, Zihnioglu F: Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 2007;70:709-711.
16. Han MH, Yoo YH, Choi YH: Sanguinarine-induced apoptosis in human leukemia U937 cells via Bcl-2 downregulation and caspase-3 activation. Chemotherapy 2008;54:157-165.
17. Westfall SD, Nilsson EE, Skinner MK: Role of triptolide as an adjunct chemotherapy for ovarian cancer. Chemotherapy 2008;54:67-76.
18. Liu J, Li X, Cheng YN, Cui SX, Chen MH, Xu WF, Tian ZG, Makuuchi M, Tang W, Qu XJ: Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil. Eur J Pharmacol 2007;574:1-7.
19. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-1465.
20. Ajisaka H, Shimizu K, Miwa K: Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma. J Surg Oncol 2003;84:89-93.
21. 2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004;40:243-251.
22. Uehara S, Gotoh K, Handa H, Tomita H, Senshuu M: Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:1545-1552.
23. Sugimoto H, Takeda S, Inoue S, Kaneko T, Watanabe K, Nakao A: Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma. Liver Int 2003;23:38-44.
24. Yuen MF, Lai CL: Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005;19:91-99.
25. Wallin R, Sane DC, Hutson SM: Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res 2002;108:221-226.
26. 2 binds 17 β-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Life Sci 2005;76:2473-2482.